Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: Future therapeutic perspectives

The Lancet

Volumn 384, Issue 9942, 2014, Pages 545-555

  Schapira, Anthony H V ^a   Olanow, C Warren ^b   Greenamyre, J Timothy ^c   Bezard, Erwan ^d,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ANTISENSE OLIGONUCLEOTIDE; BEZAFIBRATE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; EXENDIN 4; GBA PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCAGON LIKE PEPTIDE 1; HEAT SHOCK PROTEIN 70; HUNTINGTIN; HUNTINGTIN INTERACTING PROTEIN 1; INITIATION FACTOR 2ALPHA; LEUCINE RICH REPEAT KINASE 2; MITOCHONDRIAL DNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOTRANSFERASE INHIBITOR; PINK1 PROTEIN; POLYGLUTAMINE; PROTEASOME; PROTEIN; PROTEIN P53; RESVERATROL; SODIUM CHANNEL; UNCLASSIFIED DRUG; UNINDEXED DRUG; NEUROTROPHIC FACTOR; NUCLEIC ACID; PHOSPHOTRANSFERASE;

APOPTOSIS; AUTOPHAGY; AUTOPHOSPHORYLATION; BIOENERGY; CELL DEGENERATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DOWN REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUNTINGTON CHOREA; LEWY BODY; LYSOSOME; MEMBRANE POTENTIAL; MITOCHONDRION; MITOPHAGY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN MISFOLDING; PROTEIN PHOSPHORYLATION; RESPIRATORY CHAIN; REVIEW; SUBSTANTIA NIGRA PARS COMPACTA; TURNOVER TIME; UNFOLDED PROTEIN RESPONSE; UPREGULATION; WILD TYPE; ARTICLE; CALCIUM HOMEOSTASIS; CLINICAL TRIAL (TOPIC); PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RISK FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

APOPTOSIS; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN KINASES; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84906306620     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61010-2     Document Type: Review

References (109)

1. LM de Lau, MM Breteler Epidemiology of Parkinson's disease Lancet Neurol 5 2006 525 535
2. SC Warby, H Visscher, JA Collins et al. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia Eur J Hum Genet 19 2011 561 566
3. I Paradisi, A Hernández, S Arias Huntington disease mutation in Venezuela: age of onset, haplotype analyses and geographic aggregation J Hum Genet 53 2008 127 135
4. T Pringsheim, K Wiltshire, L Day, J Dykeman, T Steeves, N Jette The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis Mov Disord 27 2012 1083 1091
5. A Kaplan, BR Stockwell Therapeutic approaches to preventing cell death in Huntington disease Prog Neurobiol 99 2012 262 280
6. AH Schapira, E Tolosa Molecular and clinical prodrome of Parkinson disease: implications for treatment Nat Rev Neurol 6 2010 309 317
7. CW Olanow, K Kieburtz, AH Schapira Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 64 suppl 2 2008 S101 S110
8. AH Schapira, CW Olanow Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions JAMA 291 2004 358 364
9. V Dragalin An introduction to adaptive designs and adaptation in CNS trials Eur Neuropsychopharmacol 21 2011 153 158
10. AH Schapira Recent developments in biomarkers in Parkinson disease Curr Opin Neurol 26 2013 395 400
11. CA Ross, SJ Tabrizi Huntington's disease: from molecular pathogenesis to clinical treatment Lancet Neurol 10 2011 83 98
12. SM Hersch, HD Rosas Neuroprotection for Huntington's disease: ready, set, slow Neurotherapeutics 5 2008 226 236
13. D Bano, F Zanetti, Y Mende, P Nicotera Neurodegenerative processes in Huntington's disease Cell Death Dis 2 2011 e228
14. T Vagner, D Young, A Mouravlev Nucleic acid-based therapy approaches for huntington's disease Neurol Res Int 2012 2012 358 370
15. AH Schapira Mitochondria in the aetiology and pathogenesis of Parkinson's disease Lancet Neurol 7 2008 97 109
16. G Blander, L Guarente The Sir2 family of protein deacetylases Annu Rev Biochem 73 2004 417 435
17. KT Howitz, KJ Bitterman, HY Cohen et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 425 2003 191 196
18. MM Khan, A Ahmad, T Ishrat et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease Brain Res 1328 2010 139 151
19. D Alvarez-Fischer, J Fuchs, F Castagner et al. Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults Nat Neurosci 14 2011 1260 1266
20. I Aviles-Olmos, P Limousin, A Lees, T Foltynie Parkinson's disease, insulin resistance and novel agents of neuroprotection Brain 136 2013 374 384
21. I Aviles-Olmos, J Dickson, Z Kefalopoulou et al. Exenatide and the treatment of patients with Parkinson's disease J Clin Invest 123 2013 2730 2736
22. H Chen, DC Chan Mitochondrial dynamics - fusion, fission, movement, and mitophagy - in neurodegenerative diseases Hum Mol Genet 18 2009 R169 R176
23. G Ashrafi, TL Schwarz The pathways of mitophagy for quality control and clearance of mitochondria Cell Death Differ 20 2013 31 42
24. ES Vincow, G Merrihew, RE Thomas et al. The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo Proc Natl Acad Sci USA 110 2013 6400 6405
25. LS Tain, H Mortiboys, RN Tao, E Ziviani, O Bandmann, AJ Whitworth Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss Nat Neurosci 12 2009 1129 1135
26. X Wang, D Winter, G Ashrafi et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility Cell 147 2011 893 906
27. JH Kordower, CW Olanow, HB Dodiya et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease Brain 136 2013 2419 2431
28. C Zuccato, M Valenza, E Cattaneo Molecular mechanisms and potential therapeutical targets in Huntington's disease Physiol Rev 90 2010 905 981
29. AV Panov, CA Gutekunst, BR Leavitt et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines Nat Neurosci 5 2002 731 736
30. W Song, J Chen, A Petrilli et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity Nat Med 17 2011 377 382
31. M Gu, MT Gash, VM Mann, F Javoy-Agid, JM Cooper, AH Schapira Mitochondrial defect in Huntington's disease caudate nucleus Ann Neurol 39 1996 385 389
32. L Cui, H Jeong, F Borovecki, CN Parkhurst, N Tanese, D Krainc Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration Cell 127 2006 59 69
33. CM Cowan, MM Fan, J Fan et al. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity J Neurosci 28 2008 12725 12735
34. LR Gauthier, BC Charrin, M Borrell-Pagès et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules Cell 118 2004 127 138
35. DC Rubinsztein, P Codogno, B Levine Autophagy modulation as a potential therapeutic target for diverse diseases Nat Rev Drug Discov 11 2012 709 730
36. S Ramaswamy, JL McBride, I Han et al. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease Neurobiol Dis 34 2009 40 50
37. DJ Surmeier Calcium, ageing, and neuronal vulnerability in Parkinson's disease Lancet Neurol 6 2007 933 938
38. CS Chan, JN Guzman, E Ilijic et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease Nature 447 2007 1081 1086
39. JN Guzman, J Sanchez-Padilla, D Wokosin et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 Nature 468 2010 696 700
40. S Kang, G Cooper, SF Dunne et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease Nat Commun 3 2012 1146
41. H Fujiwara, M Hasegawa, N Dohmae et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions Nat Cell Biol 4 2002 160 164
42. S Hara, S Arawaka, H Sato et al. Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner Mol Biol Cell 24 2013 1649 1660 S1-3.
43. DG Healy, M Falchi, SS O'Sullivan the International LRRK2 Consortium Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study Lancet Neurol 7 2008 583 590
44. X Deng, N Dzamko, A Prescott et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat Chem Biol 7 2011 203 205
45. N Ramsden, J Perrin, Z Ren et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons ACS Chem Biol 6 2011 1021 1028
46. O Cooper, H Seo, S Andrabi et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease Sci Transl Med 4 2012 141ra90
47. L Alvarez-Erviti, MC Rodriguez-Oroz, JM Cooper et al. Chaperone-mediated autophagy markers in Parkinson disease brains Arch Neurol 67 2010 1464 1472
48. A McNeill, J Magalhaes, C Shen et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells Brain 137 2014 1481 1495
49. AB Singleton, M Farrer, J Johnson et al. alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003 841
50. B Winner, R Jappelli, SK Maji et al. In vivo demonstration that alpha-synuclein oligomers are toxic Proc Natl Acad Sci USA 108 2011 4194 4199
51. CW Olanow, P Brundin Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord 28 2013 31 40
52. JH Kordower, Y Chu, RA Hauser, TB Freeman, CW Olanow Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease Nat Med 14 2008 504 506
53. JY Li, E Englund, JL Holton et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation Nat Med 14 2008 501 503
54. CW Olanow, SB Prusiner Is Parkinson's disease a prion disorder? Proc Natl Acad Sci USA 106 2009 12571 12572
55. E Angot, JA Steiner, C Hansen, JY Li, P Brundin Are synucleinopathies prion-like disorders? Lancet Neurol 9 2010 1128 1138
56. P Desplats, HJ Lee, EJ Bae et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein Proc Natl Acad Sci USA 106 2009 13010 13015
57. LA Volpicelli-Daley, KC Luk, TP Patel et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death Neuron 72 2011 57 71
58. C Hansen, E Angot, AL Bergström et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells J Clin Invest 121 2011 715 725
59. AL Mougenot, S Nicot, A Bencsik et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model Neurobiol Aging 33 2012 2225 2228
60. KC Luk, V Kehm, J Carroll et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice Science 338 2012 949 953
61. PK Auluck, HY Chan, JQ Trojanowski, VM Lee, NM Bonini Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease Science 295 2002 865 868
62. J Bové, M Martínez-Vicente, M Vila Fighting neurodegeneration with rapamycin: mechanistic insights Nat Rev Neurosci 12 2011 437 452
63. ME Gegg, D Burke, SJR Heales et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains Ann Neurol 72 2012 455 463
64. MW Cleeter, KY Chau, C Gluck et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage Neurochem Int 62 2013 1 7
65. LD Osellame, AA Rahim, IP Hargreaves et al. Mitochondria and quality control defects in a mouse model of Gaucher disease - links to Parkinson's disease Cell Metab 17 2013 941 953
66. JR Mazzulli, YH Xu, Y Sun et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies Cell 146 2011 37 52
67. AH Schapira, ME Gegg Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease Proc Natl Acad Sci USA 110 2013 3214 3215
68. SP Sardi, J Clarke, C Viel et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies Proc Natl Acad Sci USA 110 2013 3537 3542
69. T Bartels, JG Choi, DJ Selkoe α-synuclein occurs physiologically as a helically folded tetramer that resists aggregation Nature 477 2011 107 110
70. E Masliah, E Rockenstein, M Mante et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease PLoS One 6 2011 e19338
71. E Masliah, E Rockenstein, A Adame et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease Neuron 46 2005 857 868
72. EJ Bae, HJ Lee, E Rockenstein et al. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission J Neurosci 32 2012 13454 13469
73. CW Olanow, DP Perl, GN DeMartino, KS McNaught Lewy-body formation is an aggresome-related process: a hypothesis Lancet Neurol 3 2004 496 503
74. EJ Benner, R Banerjee, AD Reynolds et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons PLoS One 3 2008 e1376
75. JJ Hoozemans, ES van Haastert, P Eikelenboom, RA de Vos, JM Rozemuller, W Scheper Activation of the unfolded protein response in Parkinson's disease Biochem Biophys Res Commun 354 2007 707 711
76. JA Moreno, H Radford, D Peretti et al. Sustained translational repression by eIF2α-P mediates prion neurodegeneration Nature 485 2012 507 511
77. L Alvarez-Erviti, Y Seow, H Yin, C Betts, S Lakhal, MJ Wood Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 29 2011 341 345
78. S El-Andaloussi, Y Lee, S Lakhal-Littleton et al. Exosome-mediated delivery of siRNA in vitro and in vivo Nat Protoc 7 2012 2112 2126
79. H Braak, K Del Tredici, U Rüb, RA de Vos, EN Jansen Steur, E Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2003 197 211
80. L Alvarez-Erviti, Y Seow, AH Schapira et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission Neurobiol Dis 42 2011 360 367
81. M DiFiglia, E Sapp, KO Chase et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990 1993
82. A Yamamoto, JJ Lucas, R Hen Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease Cell 101 2000 57 66
83. PS Ramachandran, MS Keiser, BL Davidson Recent advances in RNA interference therapeutics for CNS diseases Neurotherapeutics 10 2013 473 485
84. W San Sebastian, L Samaranch, AP Kells, J Forsayeth, KS Bankiewicz Gene therapy for misfolding protein diseases of the central nervous system Neurotherapeutics 10 2013 498 510
85. SL DeVos, TM Miller Antisense oligonucleotides: treating neurodegeneration at the level of RNA Neurotherapeutics 10 2013 486 497
86. HB Kordasiewicz, LM Stanek, EV Wancewicz et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis Neuron 74 2012 1031 1044
87. J Hu, M Matsui, KT Gagnon et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs Nat Biotechnol 27 2009 478 484
88. R Grondin, MD Kaytor, Y Ai et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum Brain 135 2012 1197 1209
89. JL McBride, MR Pitzer, RL Boudreau et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease Mol Ther 19 2011 2152 2162
90. JD Godin, K Colombo, M Molina-Calavita et al. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis Neuron 67 2010 392 406
91. J Hu, J Liu, DR Corey Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism Chem Biol 17 2010 1183 1188
92. KT Gagnon, HM Pendergraff, GF Deleavey et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat Biochemistry 49 2010 10166 10178
93. JB Carroll, SC Warby, AL Southwell et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/ allele-specific silencing of mutant huntingtin Mol Ther 19 2011 2178 2185
94. A Messer, SN Joshi Intrabodies as neuroprotective therapeutics Neurotherapeutics 10 2013 447 458
95. Y Okamoto, Y Nagai, N Fujikake et al. Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch Biochem Biophys Res Commun 378 2009 634 639
96. Y Nagai, N Fujikake, K Ohno et al. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila Hum Mol Genet 12 2003 1253 1259
97. PO Bauer, A Goswami, HK Wong et al. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein Nat Biotechnol 28 2010 256 263
98. HA Popiel, T Takeuchi, JR Burke et al. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases Neurotherapeutics 10 2013 440 446
99. B Calamini, DC Lo, LS Kaltenbach Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration Neurotherapeutics 10 2013 400 415
100. AL Peterson, JG Nutt Treatment of Parkinson's disease with trophic factors Neurotherapeutics 5 2008 270 280
101. WJ Marks Jr, RT Bartus, J Siffert et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial Lancet Neurol 9 2010 1164 1172
102. M Decressac, B Kadkhodaei, B Mattsson, A Laguna, T Perlmann, A Bjorklund alpha-synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons Sci Transl Med 4 2012 163ra156
103. B Kadkhodaei, A Alvarsson, N Schintu et al. Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons Proc Natl Acad Sci USA 110 2013 2360 2365
104. Parkinson Study Group PRECEPT Investigators Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease Neurology 69 2007 1480 1490
105. G Kroemer, L Galluzzi, P Vandenabeele the Nomenclature Committee on Cell Death 2009 Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 Cell Death Differ 16 2009 3 11
106. T Kiechle, A Dedeoglu, J Kubilus et al. Cytochrome C and caspase-9 expression in Huntington's disease Neuromolecular Med 1 2002 183 195
107. JS Steffan, A Kazantsev, O Spasic-Boskovic et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription Proc Natl Acad Sci USA 97 2000 6763 6768
108. MA Kalchman, HB Koide, K McCutcheon et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain Nat Genet 16 1997 44 53
109. SA Choi, SJ Kim, KC Chung Huntingtin-interacting protein 1-mediated neuronal cell death occurs through intrinsic apoptotic pathways and mitochondrial alterations FEBS Lett 580 2006 5275 5282